Search / Trial NCT06614010

Effect of Different Administration Routes of Dexmedetomidine Combined with Ultrasound-Guided Fascia Iliaca Block on Emergence Agitation After Hip Replacement Surgery

Launched by QIANFOSHAN HOSPITAL · Sep 23, 2024

Trial Information

Current as of December 21, 2024

Recruiting

Keywords

Fascia Iliaca Block Dexmedetomidine Emergence Agitation Ropivacaine Analgesic Mechanism

ClinConnect Summary

This clinical trial is studying how different ways of giving a medication called dexmedetomidine, along with a special pain management technique known as the fascia iliaca block, can help reduce a condition called emergence agitation after hip replacement surgery. Emergence agitation is when patients feel confused or restless as they wake up from anesthesia. The goal is to find the best way to administer dexmedetomidine to improve recovery after surgery.

To be eligible for this study, participants need to be between 18 and 65 years old and have a hip joint condition that requires surgery. They should be in good overall health without major heart, lung, or liver issues and should not have a history of mental health problems or long-term use of sedatives. Participants will receive detailed information about the study and will need to agree to take part by signing a consent form. This trial is currently recruiting patients, and it aims to help improve the recovery experience for those undergoing hip replacement surgery.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. age between 18 and 65 years, with no restriction on gender
  • 2. diagnosis of hip joint disease necessitating hip arthroplasty
  • 3. ASA grade I-II
  • 4. no significant cardiopulmonary, hepatic, or renal dysfunction prior to the operation
  • 5. no history of psychiatric disorders or long-term use of sedative medications prior to the operation
  • 6. signing of an informed consent form to voluntarily participate in the study.
  • Exclusion Criteria:
  • 1. patients allergic to or with contraindications to ropivacaine or dexmedetomidine
  • 2. patients exhibiting symptoms of agitation or delirium prior to the procedure
  • 3. patients with severe central or peripheral nervous system disorders
  • 4. patients with coagulation disorders or receiving anticoagulant therapy
  • 5. pregnant or breastfeeding women
  • 6. patients who received other medications or treatments prior to the procedure that might affect the study results
  • 7. patients unable to cooperate with the study or intolerant to ultrasound-guided iliofascial block

About Qianfoshan Hospital

Qianfoshan Hospital is a leading medical institution dedicated to advancing healthcare through innovative clinical research and trials. Located in Shandong Province, China, the hospital is renowned for its commitment to excellence in patient care and medical education. With a multidisciplinary team of experienced professionals, Qianfoshan Hospital focuses on a wide range of therapeutic areas, striving to enhance treatment options and improve patient outcomes. The institution actively collaborates with various stakeholders to ensure the highest standards of ethics and efficacy in its clinical research endeavors.

Locations

Jinan, Shandong, China

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0